Menopur (Menotrophin)

Menotrophin contains both FSH and LH activity. FSH binds to granulosa‑cell receptors, promoting follicle growth and estrogen production, while LH stimulates theca‑cell receptors for androgen synthesis and final maturation. Together they synchronize follicle development and trigger ovulation.

The prescribed dose of Menopur is individualized by the treating physician based on the patient’s ovarian response, treatment protocol, and monitoring results. Dosage may be adjusted during the stimulation cycle according to ultrasound and hormone levels.

Menopur is contraindicated during pregnancy because it is intended to induce ovulation and ovarian stimulation. Safety data for breastfeeding are lacking; the medication should not be used by nursing mothers unless a healthcare professional determines that the benefits outweigh potential risks.

To request Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to Menopur is recombinant FSH (e.g., follitropin alfa). Menopur, derived from human pituitary extracts, provides both FSH and LH activity in a single preparation, whereas recombinant products typically contain only FSH and may require separate LH supplementation. Choice depends on clinical protocol, patient response, and physician preference.

Menopur must be stored refrigerated at 2–8 °C, protected from light, and must not be frozen or shaken. Vials should be kept in the original carton until use, and any unused portion should be discarded according to local regulations after the recommended in‑use period.

Menopur is supplied as a sterile solution for subcutaneous injection. The dose is drawn into a syringe and injected into the subcutaneous tissue of the abdomen, thigh, or upper arm, following the administration technique described in the prescribing information and under medical supervision.

The most serious adverse events associated with Menopur include ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, rapid weight gain, and, in severe cases, thromboembolism or renal failure, as well as multiple pregnancy and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these conditions.

Menopur is contraindicated in women who are pregnant, have known hypersensitivity to menotrophin or any component of the formulation, have active ovarian cysts, uncontrolled thyroid disease, or severe ovarian failure. It should also be used with caution in patients with renal or hepatic impairment and those at high risk for thromboembolic events.